Artelo Biosciences Inc. (ARTL)
NASDAQ (CM) NASDAQ (CM) Primary Summary
New Strong Sell Stocks for March 6th
ARTL, KW and KRP have been added to the Zacks Rank #5 (Strong Sell) List on March 6, 2025.
Artelo Biosciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 2 | $15 | $1.54 | -$13.46 | -89.73% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 1 | $1.1 | $0.72 | -$0.38 | -34.55% |
| BO Brian Oliveira Clear Street Group Inc. | 100 | $758 | $77 | -$681 | -89.84% |
 Kevin Bresler TD Waterhouse Canada Inc. | 2 | $2.2 | $1.54 | -$0.66 | -30% |
Artelo Biosciences Inc. (ARTL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Artelo Biosciences Inc. ever had a stock split?
Artelo Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Gregory D. Gorgas CEO | NASDAQ (CM) Exchange | 04301G706 CUSIP |
| US Country | 7 Employees | - Last Dividend | 10 Mar 2026 Last Split | 21 Jun 2019 IPO Date |
Overview
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical entity specializing in the innovation and market introduction of therapeutics that regulate the endocannabinoid system. Initially operating under the name Reactive Medical, Inc., the company underwent a rebranding to Artelo Biosciences, Inc. in April 2017. Founded in 2011, its headquarters are located in Solana Beach, California. Artelo Biosciences is dedicated to addressing a variety of medical conditions through its advanced, cannabinoid-based treatment options, highlighting its role in the evolving landscape of medical cannabis research.
Products and Services
-
ART27.13:
This product is a pioneering synthetic dual cannabinoid G protein-coupled receptor agonist. Currently in a Phase 1b/2a clinical trial, ART27.13 is being explored as a potential treatment for anorexia associated with cancer. This novel therapeutic approach signifies Artelo Biosciences’ commitment to addressing the complex needs of cancer patients, especially those suffering from cancer-induced anorexia which greatly affects the patient's quality of life and prognosis.
-
ART12.11:
A synthetic cannabidiol cocrystal, ART12.11, is under development to treat inflammatory bowel disease and post-traumatic stress disorder (PTSD). The utilization of cannabidiol, a compound derived from the cannabis plant, illustrates Artelo Biosciences’ innovative approach in leveraging the therapeutic potentials of cannabinoids beyond their conventional use, with a specific focus on non-psychoactive components for treating a broad spectrum of disorders.
-
ART26.12:
As a fatty acid binding protein 5 inhibitor, ART26.12 represents Artelo Biosciences’ forward-thinking in targeting breast and prostate cancer, neuropathic and nociceptive pain, as well as anxiety disorders, including PTSD. Through the inhibition of specific proteins involved in the development of these conditions, ART26.12 may offer a novel therapeutic pathway for patients, underscoring Artelo Biosciences' dedication to pioneering cancer and pain management solutions alongside mental health treatments.
